Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVS NASDAQ:NUAI NASDAQ:USAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$14.27-4.4%$13.32$3.96▼$26.95$1.20B0.822.38 million shs1.26 million shsNUAINew Era Energy & Digital$3.98-10.8%$5.07$0.32▼$9.44$403.14M1.216.41 million shs5.75 million shsUSARUSA Rare Earth$15.91-8.1%$22.97$10.91▼$43.98$3.55B2.4517.50 million shs12.21 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals-0.33%-7.21%+25.38%-0.80%+257.79%NUAINew Era Energy & Digital+7.47%+2.53%-20.78%-10.44%+445,999,900.00%USARUSA Rare Earth-4.84%-6.18%-24.80%-6.08%+11.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$14.27-4.4%$13.32$3.96▼$26.95$1.20B0.822.38 million shs1.26 million shsNUAINew Era Energy & Digital$3.98-10.8%$5.07$0.32▼$9.44$403.14M1.216.41 million shs5.75 million shsUSARUSA Rare Earth$15.91-8.1%$22.97$10.91▼$43.98$3.55B2.4517.50 million shs12.21 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals-0.33%-7.21%+25.38%-0.80%+257.79%NUAINew Era Energy & Digital+7.47%+2.53%-20.78%-10.44%+445,999,900.00%USARUSA Rare Earth-4.84%-6.18%-24.80%-6.08%+11.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVSCorvus Pharmaceuticals 2.71Moderate Buy$33.33133.59% UpsideNUAINew Era Energy & Digital 2.60Moderate Buy$10.33159.63% UpsideUSARUSA Rare Earth 2.80Moderate Buy$36.83131.51% UpsideCurrent Analyst Ratings BreakdownLatest CRVS, NUAI, and USAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2026CRVSCorvus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/7/2026NUAINew Era Energy & Digital New Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.007/7/2026NUAINew Era Energy & Digital B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.006/4/2026USARUSA Rare Earth Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$40.006/4/2026USARUSA Rare Earth Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026USARUSA Rare Earth BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/1/2026USARUSA Rare Earth Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$39.006/1/2026USARUSA Rare Earth Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$39.005/22/2026NUAINew Era Energy & Digital Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026USARUSA Rare Earth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)5/14/2026USARUSA Rare Earth Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $35.00(Data available from 7/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVSCorvus PharmaceuticalsN/AN/A$0.12 per share118.10$0.73 per shareN/ANUAINew Era Energy & Digital$1.36M296.14N/AN/A($0.05) per share-79.60USARUSA Rare Earth$1.64M2,163.76N/AN/A$3.34 per share4.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVSCorvus Pharmaceuticals-$15.28M-$0.52N/AN/AN/AN/A-38.92%-35.75%8/6/2026 (Estimated)NUAINew Era Energy & Digital-$29.59M-$0.98N/AN/AN/A-2,592.43%-687.58%-101.21%N/AUSARUSA Rare Earth-$297.56M-$3.92N/AN/AN/AN/A-15.39%-10.08%N/ALatest CRVS, NUAI, and USAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026CRVSCorvus Pharmaceuticals-$0.17N/AN/AN/AN/AN/A5/15/2026Q1 2026NUAINew Era Energy & DigitalN/A-$0.16N/A-$0.16N/A$0.80 million5/13/2026Q1 2026USARUSA Rare Earth-$0.16-$0.12+$0.04-$0.34N/A$5.70 million5/7/2026Q1 2026CRVSCorvus Pharmaceuticals-$0.14-$0.15-$0.01-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/ANUAINew Era Energy & DigitalN/AN/AN/AN/AN/AUSARUSA Rare EarthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVSCorvus PharmaceuticalsN/A19.8119.81NUAINew Era Energy & DigitalN/A0.100.10USARUSA Rare EarthN/A36.2935.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVSCorvus Pharmaceuticals46.64%NUAINew Era Energy & Digital21.90%USARUSA Rare EarthN/AInsider OwnershipCompanyInsider OwnershipCRVSCorvus Pharmaceuticals19.70%NUAINew Era Energy & Digital4.07%USARUSA Rare Earth9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVSCorvus Pharmaceuticals3084.09 million67.52 millionOptionableNUAINew Era Energy & DigitalN/A101.29 million97.17 millionN/AUSARUSA Rare EarthN/A223.04 million202.74 millionN/ACRVS, NUAI, and USAR HeadlinesRecent News About These CompaniesUSA Rare Earth (NASDAQ:USAR) Shares Down 8.1% - Here's What Happened1 hour ago | marketbeat.comUSA Rare Earth (NASDAQ:USAR) Stock Price Down 4.8% - Here's What HappenedJuly 15 at 5:19 PM | marketbeat.comUSA Rare Earth (NASDAQ:USAR) Stock Price Up 5.7% - Should You Buy?July 14 at 5:19 PM | marketbeat.comUSA Rare Earth produces commercial-grade Dy, NdPr oxide from recycled magnet scrapJuly 14 at 12:21 PM | seekingalpha.comUSA Rare Earth Produces Commercial Grade Dysprosium Oxide and Neodymium-Praseodymium Oxide Samples from Recycled Magnet Material at Wheat Ridge FacilityJuly 14 at 7:21 AM | finance.yahoo.comUSA Rare Earth Produces Commercial Grade Dysprosium Oxide and Neodymium-Praseodymium Oxide Samples from Recycled Magnet Material at Wheat Ridge FacilityJuly 14 at 7:00 AM | globenewswire.comHyProMag is the Magnet Opportunity Hiding in America's Scrap HeapJuly 13 at 8:45 PM | finance.yahoo.comHere's Why USA Rare Earth Stock Rocketed 81% Higher in the First Half of 2026July 13 at 8:45 PM | fool.comUSA Rare Earth (NASDAQ:USAR) Stock Price Down 6.9% - What's Next?July 13 at 5:20 PM | marketbeat.comSovran Advisors LLC Cuts Stock Holdings in USA Rare Earth Inc. $USARJuly 12, 2026 | marketbeat.comUSA Rare Earth (NASDAQ:USAR) Trading Down 2.1% - Here's What HappenedJuly 12, 2026 | americanbankingnews.com3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk (USAR)...July 12, 2026 | marketbeat.comUSA Rare Earth (NASDAQ:USAR) Trading Down 2.1% - Should You Sell?July 10, 2026 | marketbeat.comUSA Rare Earth (NASDAQ:USAR) Stock Price Up 2.3% - Here's WhyJuly 9, 2026 | marketbeat.comRare Earth Talent Scramble Lures 86-Year-Old From RetirementJuly 9, 2026 | finance.yahoo.comCRML, UUUU, USAR, ALOY, GLND: Greenland’s Rare-Earth Trade Draws Investors As Trump Revives Arctic AmbitionsJuly 8, 2026 | stocktwits.comSCommerce secretary's role in $1.6B USA Rare Earth deal probed by Democrat lawmakersJuly 7, 2026 | msn.comDemocrats Probe Cantor Fitzgerald Ties in USA Rare Earth DealJuly 7, 2026 | finance.yahoo.comWhat's driving US critical minerals stocks higher on Tuesday?July 7, 2026 | invezz.comIMP Materials Trades at a Premium Valuation: How to Play the Stock?July 6, 2026 | finance.yahoo.comHere's Why Shares in USA Rare Earth Slumped 23% in JuneJuly 5, 2026 | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026SK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026Could a Tesla-SpaceX Merger Be Closer Than Investors Think?By Sam Quirke | June 17, 2026USA Rare Earth Just Moved Closer to Commercial RealityBy Jeffrey Neal Johnson | June 18, 2026CRVS, NUAI, and USAR Company DescriptionsCorvus Pharmaceuticals NASDAQ:CRVS$14.27 -0.65 (-4.36%) Closing price 04:00 PM EasternExtended Trading$14.34 +0.07 (+0.49%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.New Era Energy & Digital NASDAQ:NUAI$3.98 -0.48 (-10.76%) Closing price 04:00 PM EasternExtended Trading$4.02 +0.04 (+1.11%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.New Era Energy & Digital, Inc., operates as an exploration and production platform, engages in the exploration, development, and production of helium, oil and natural gas, and natural gas liquids in the United States. The company owns and operates a portfolio of approximately 137,000 acres in Southeast New Mexico. Its flagship Pecos Slope Field covering an area of 1893 square kilometers located 20 miles north of Roswell, New Mexico. It serves Tier 2 gas companies and balloon gas distributors. The company was formerly known as New Era Helium, Inc. and changed its name to New Era Energy & Digital, Inc. in August 2025. New Era Energy & Digital, Inc. is based in Midland, Texas.USA Rare Earth NASDAQ:USAR$15.91 -1.40 (-8.09%) Closing price 04:00 PM EasternExtended Trading$15.89 -0.02 (-0.13%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Revving Up Returns: Big Banks Race Through the Rate Plateau Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money AI’s Power Crunch Fuels a Pivot for These 2 Oilfield Stocks PayPal Stock Surges on $53 Billion Stripe-Advent Buyout Bid Toast’s Comeback Story Is Getting Harder for Wall Street to Ignore Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
